$OSTXSep 2, 2026, 11:21 AMAI processed
OSTX: OST‑HER2 showed positive Phase 2b results; FDA/MHRA/EMA meetings set and BLA/CMAA filings targeted Q4 2026
AI Summary
OS Therapies says OST‑HER2's Phase 2b reported a clinically significant benefit on the 12‑month event‑free survival primary endpoint and an overall survival secondary endpoint, and it plans regulatory interactions (FDA Type C statistical meeting mid‑Sept 2026 plus MHRA/EMA meetings) before seeking Accelerated Approval BLA and Conditional Marketing Authorisation submissions in Q4 2026. The company expects RMAT/rolling review decisions to follow the FDA meeting, aims to file under accelerated/conditional pathways (with potential Priority Review Voucher eligibility if a U.S. BLA is granted), and plans a confirmatory Phase 3 CTA and final 3‑year OS data also in Q4 2026.
Positives
- Phase 2b reportedly met the 12‑month EFS primary endpoint and showed overall survival benefit
- Multiple expedited designations in place (FDA ODD, FTD, RPDD; EMA ODD, FTD, ATMP) and RMAT resubmission support accelerated review pathways
- Company expects FDA Type C meeting mid‑Sept 2026 and plans to request rolling review and submit BLA (Accelerated Approval) and CMAAs in Q4 2026
Negatives
- Regulatory decisions and timing are uncertain and not guaranteed
- Any approval pathway appears conditional and will require a confirmatory Phase 3 (CTA planned for Q4 2026)
- Potential Priority Review Voucher value is uncertain despite a recent comparable PRV sale ($220M)